- Home
- BMGL vs SCLX Comparison
BMGL vs SCLX Comparison
Compare BMGL & SCLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMGL
- SCLX
- Stock Information
- Founded
- BMGL 2001
- SCLX 2011
- Country
- BMGL Singapore
- SCLX United States
- Employees
- BMGL N/A
- SCLX N/A
- Industry
- BMGL
- SCLX Biotechnology: Pharmaceutical Preparations
- Sector
- BMGL
- SCLX Health Care
- Exchange
- BMGL NYSE
- SCLX Nasdaq
- Market Cap
- BMGL 32.7M
- SCLX 34.3M
- IPO Year
- BMGL 2025
- SCLX N/A
- Fundamental
- Price
- BMGL $2.25
- SCLX $6.46
- Analyst Decision
- BMGL
- SCLX Strong Buy
- Analyst Count
- BMGL 0
- SCLX 3
- Target Price
- BMGL N/A
- SCLX $367.50
- AVG Volume (30 Days)
- BMGL 5.2M
- SCLX 93.4K
- Earning Date
- BMGL 01-01-0001
- SCLX 08-12-2025
- Dividend Yield
- BMGL N/A
- SCLX N/A
- EPS Growth
- BMGL N/A
- SCLX N/A
- EPS
- BMGL 0.02
- SCLX N/A
- Revenue
- BMGL $7,342,469.00
- SCLX $50,710,000.00
- Revenue This Year
- BMGL N/A
- SCLX $107.00
- Revenue Next Year
- BMGL N/A
- SCLX $82.52
- P/E Ratio
- BMGL $153.47
- SCLX N/A
- Revenue Growth
- BMGL 2.28
- SCLX 7.79
- 52 Week Low
- BMGL $0.91
- SCLX $3.60
- 52 Week High
- BMGL $9.40
- SCLX $73.50
- Technical
- Relative Strength Index (RSI)
- BMGL N/A
- SCLX 61.59
- Support Level
- BMGL N/A
- SCLX $6.00
- Resistance Level
- BMGL N/A
- SCLX $6.76
- Average True Range (ATR)
- BMGL 0.00
- SCLX 0.45
- MACD
- BMGL 0.00
- SCLX 0.10
- Stochastic Oscillator
- BMGL 0.00
- SCLX 86.55
About BMGL BASEL MEDICAL GROUP LTD
Basel Medical Group Ltd provides general and subspecialized orthopedic, trauma and sports medicine services such as knee/hip replacements, sports medicine/surgery, spine surgery, foot/ankle surgery and minimally invasive orthopedic procedures, as well as neurosurgical treatments. Key revenue is generated from Singapore.
About SCLX Scilex Holding Company
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.